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ABSTRACT
This study reviewed retrospectively the clinical characteristics of 28 cancer patients with fungal
osteoarticular infections (FOAIs) between 1995 and 2005. Most patients (26; 93%) had haematological
malignancies (19 had leukaemia); half (14) were allogeneic stem-cell transplant recipients. Twelve
patients (43%) had severe neutropenia (£ 100 ⁄mm3) with a mean duration of 65 days (range 10–
500 days), and ten (36%) patients had received a signiﬁcant dose of corticosteroids. Most (19; 68%)
FOAIs were caused by contiguous extension, while nine (32%) were associated with haematogenous
spread. Pain, joint instability and local drainage were seen in 28 (100%), six (21%), and seven (25%)
patients, respectively. Sixteen (57%) patients had symptoms for < 1 month. The sinuses (ten; 36%)
and the vertebral spine (six; 21%) were the most common sites involved. Moulds were the
predominant pathogens: Aspergillus fumigatus (two); non-fumigatus Aspergillus spp. (eight); non-
speciﬁed Aspergillus spp. (three); Fusarium spp. (six); Zygomycetes (ﬁve); Scedosporium apiospermum
(two); and Exserohilum sp. (one). Candida was the causative pathogen in four cases (including two
cases of mixed FOAIs). Arthritis and post-operative FOAIs were both uncommon manifestations,
occurring in two patients each. All patients received systemic antifungal therapy (combinations in 20
cases), and 19 cases underwent adjunctive surgery. The crude mortality rates (at 12 weeks) were
44% (9 ⁄ 20) in the patients who underwent surgery and antifungal therapy vs. 33% (2 ⁄ 6) in patients
who received antifungal therapy alone (p not signiﬁcant). FOAI is a rare, yet severe, manifestation of
localised or systemic mycoses, caused predominantly by moulds, and is seen typically in patients
with haematological malignancies.
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INTRODUCTION
Cancer patients are at high risk for opportunistic
invasive fungal infections because of predispo-
sing factors such as chemotherapy-induced
neutropenia, use of systemic corticosteroids,
indwelling central venous catheters, parenteral
nutrition and major surgery [1–3]. Fungal osteo-
articular infections (FOAIs) are uncommon enti-
ties that often escape early detection [4,5]. Skeletal
involvement results most often from the haema-
togenous spread of the fungus from a primary site
of infection, usually the lungs or indwelling
central venous catheters [6]. However, in some
instances, joint infection and, to a lesser degree,
bone infection may occur as a result of direct
inoculation of the organism during trauma, sur-
gery, arthrocentesis or therapeutic joint injection
[7–11].
There is a scarcity of literature concerning
FOAIs, particularly in patients with cancer; most
studies consist of case reports or small case series
[4–17]. Therefore, the present study sought to
deﬁne the characteristics of patients with FOAIs
who received care at a comprehensive cancer
centre during the past 10 years.
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MATERIALS AND METHODS
After obtaining institutional review board approval, the study
reviewed retrospectively the medical records of all patients
with FOAIs who received care at the University of Texas M. D.
Anderson Cancer Center (Houston, TX, USA) between January
1995 and April 2005. Patients with FOAIs were identiﬁed by a
review of clinical microbiology records, autopsy and histopa-
thology databases, and the hospital discharge databases.
Information was collected concerning patient demograph-
ics, type and status of the underlying malignancy at the time of
FOAI diagnosis, receipt of a bone marrow or stem-cell
transplant, risk-factors for invasive fungal infections, and
speciﬁc risk-factors for osteoarticular infections at the time of
FOAI diagnosis or within the preceding 1-month period.
Speciﬁcally, the study determined the presence and duration
of severe neutropenia, receipt of corticosteroids (cumulative
dose and duration), presence of graft vs. host disease, diabetes
mellitus or hyperglycaemia, malnutrition, underlying hepatic
and renal insufﬁciency, surgery or trauma within the 1-month
period preceding the diagnosis of FOAI, presence of an
indwelling central venous catheter, and receipt of hyper-
alimentation. Information concerning the treatment received
for the FOAI, including surgery, as well as the use of an
antifungal agent within 3 months of the diagnosis of FOAI (the
type of agent used, dose and duration of therapy, and whether
the agent was given as prophylaxis or as empirical, pre-
emptive or targeted antifungal therapy), was also collected.
Fungal isolates were identiﬁed according to standard micro-
biological criteria. Outcome was assessed as crude mortality at
12 weeks from diagnosis of FOAI.
Deﬁnitions
For the purpose of this study, as there is no standardised
deﬁnition, a diagnosis of FOAI was considered deﬁnite when
cultures or histopathology of bone tissue were positive for
fungi. A diagnosis of FOAI was considered probable when
there was clinical or radiological evidence of osteoarticular
infection, histologically or microbiologically conﬁrmed inva-
sive fungal infection in an adjacent site (e.g., sinuses), and no
alternative cause of osteoarticular infection. FOAI was consid-
ered to be acute when the duration of symptoms and ⁄or signs
before diagnosis was £ 4 weeks, and chronic when the
duration of symptoms and ⁄or signs before diagnosis was
> 4 weeks. Severe neutropenia was deﬁned as a neutrophil
count £ 100 ⁄mm3 for > 10 days. Signiﬁcant steroid use was
deﬁned as a cumulative steroid dose of ‡ 600 mg of predni-
sone, or an equivalent dose of another steroid, within the 4-
week period before the diagnosis of FOAI. Malnutrition was
deﬁned as a serum albumin level of £ 3 mg ⁄dL at the time of
diagnosis of FOAI. Renal insufﬁciency was deﬁned as serum
creatinine ‡ 2 mg ⁄dL at the time of diagnosis of FOAI. Hepatic
insufﬁciency was deﬁned by a Child Pugh score of ‡ 7, or
cirrhosis resulting from any cause, at the time of diagnosis of
FOAI.
Statistical analysis
Fisher’s exact test and Wilcoxon’s test were used for categor-
ical and discrete variables, respectively, as appropriate. The
Mann–Whitney U-test was used for statistical analysis of
continuous variables. A two-sided p value < 0.05 was
considered to be statistically signiﬁcant. All analyses were
performed using Prism software v.4 (GraphPad Software, San
Diego, CA, USA).
RESULTS
Thirty-one patients were identiﬁed with FOAIs; of
these, three had no underlying malignancy (ini-
tially referred because of FOAI mimicking bone
cancer) and were excluded from further analysis.
Of the 28 remaining patients, 24 had deﬁnite and
four had probable FOAIs. The demographics and
clinical characteristics of patients with FOAIs are
shown in Table 1. Most patients had advanced
haematological malignancies and typical risk-
factors for invasive fungal infections, such as a
history of haematopoietic stem-cell transplanta-
tion (57%), severe graft vs. host disease (46%),
severe neutropenia (43%), and receipt of a signi-
Table 1. Demographics and clinical characteristics of 28
cancer patients with fungal osteoarticular infection (FOAI)
Characteristic n (%)
Median age in years (range) 52 (23-89)
Male ⁄ female 15 ⁄ 13
Underlying malignancy
Haematologicala 26 (93)
Solid tumourb 2 (7)
Severe neutropeniac 12 (43)
Haematopoietic stem-cell transplant 16 (57)
Autologous 2 (13)
Allogeneic 14 (87)
Graft vs. host disease
Acute 7 (25)
Chronic 6 (21)
Signiﬁcant corticosteroid use 10 (36)
Hepatic insufﬁciency 15 (54)
Renal insufﬁciency 12 (43)
Recent surgery 2 (7)
Recent trauma 2 (7)
Intravenous hyper-alimentation 4 (14)
Indwelling central venous catheter 17 (61)
Alcohol abuse 1 (4)
Peripheral vascular disease 2 (7)
Malnutrition (serum albumin £ 3 mg ⁄dL) 18 (64)






Foreign body 2 (7)
Source of FOAI
Contiguous spread 19 (68)




aThere were nine patients with acute myelogenous leukaemia, three with chronic
myelogenous leukaemia, ﬁve each with chronic lymphocytic leukaemia and non-
Hodgkin’s lymphoma, two with myelodysplastic syndrome, and one each with
multiple myeloma and Hodgkin’s lymphoma.
bOne each with melanoma and osteosarcoma.
cNeutropenia at the time of FOAI diagnosis.
dThree patients had a mixed fungal infection: one with Aspergillus ﬂavus and
Candida albicans, one with Rhizopus and Candida tropicalis, and one with A. ﬂavus and
Fusarium).
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ﬁcant dose of corticosteroids (36%) (Table 1);
additional predisposing factors included the pres-
ence of indwelling central venous catheters (61%)
and hyper-alimentation (14%). Co-morbidities
were also present in most (91%) of the patients;
none had a history of intra-articular steroid
injection or drug abuse.
Clinical presentation of FOAIs
FOAIs were acquired more frequently from a
contiguous site (19 ⁄ 28; 68%) than from haemato-
genous spread. Multifocal bone involvement was
seen in only one patient. Most (86%) patients had
been receiving systemic antifungal agents at the
time of diagnosis of FOAI (ﬂuconazole in 11
patients, amphotericin B-based regimens in three,
voriconazole in eight, and itraconazole in two).
FOAIs were considered to be acute in most (57%)
patients, manifesting predominantly with pain at
the involved site (100%); fever (32%), joint symp-
toms (25%) and drainage from the affected site
(25%) were encountered less commonly. The
presence of hardware was seen in only two
patients with FOAIs (one with an intra-medullary
nail in the tibia, and one with a femoral modular
prosthesis).
More than half of the 19 patients with FOAIs
resulting from contiguous spread had sinusitis
(56%), with involvement of the ethmoid (ﬁve
patients), maxillary (four) and sphenoid (one)
bones. Other sites involved were the vertebrae
(two patients), tibia (two), ﬁbula (one), distal
phalanx of toe (two), ﬁfth metatarsal (one) and
mandible (one). Among the nine patients with
FOAIs resulting from haematogenous spread,
four had vertebral involvement, one had involve-
ment of the second toe, one had an FOAI of the
radius, one had an FOAI of the triquetral bone in
the wrist, and one had multifocal involvement of
the left wrist and left ulna, as well as septic
arthritis with an FOAI of the knee. There were no
signiﬁcant differences in risk-factors and clinical
characteristics between the patients with FOAIs
with sinusitis and those with FOAIs without
sinusitis (Table 2).
The most common fungi isolated were moulds
(24; 86%), comprising Aspergillus spp. (n = 10),
namely Aspergillus ﬂavus, Aspergillus terreus, As-
pergillus fumigatus and Aspergillus nidulans in four,
three, two and one patient(s), respectively,
and non-Aspergillus moulds (n = 14), comprising
Fusarium spp. (six), Zygomycetes (ﬁve), Scedospo-
rium apiospermum (two) and Exserohilum (one);
there were four culture-negative cases in which
the diagnosis—Aspergillus spp. (three) and Zyg-
omycetes (one)—was based on histopathology.
There were four FOAIs caused by yeasts (Candida
albicans and Candida tropicalis, two each), inclu-
ding two cases of mixed FOAIs. There was no
case of FOAI caused by endemic fungi. Three
patients had a mixed FOAI caused by more than
one fungus; all mixed FOAIs were associated with
contiguous spread, including two cases of sinus-
itis and one case of mandible bone involvement.
Aspergillus spp. accounted for most (7 ⁄ 9; 78%)
FOAIs associated with haematogenous spread,
but were encountered less frequently in FOAIs
associated with contiguous spread (6 ⁄ 19; 32%),
with Zygomycetes (5 ⁄ 19; 26%) being the next
most common pathogens. In the vast majority of
cases of FOAIs, diagnosis was established by
histopathology (22 ⁄ 28; 79%) and ⁄ or bone culture
(24 ⁄ 28; 86%).
Treatment
Most (20 ⁄ 28; 71%) patients received combination
antifungal therapy. The mean duration of treat-
ment was 5 months (median 3 months; range
11 days to 18 months). Nineteen of the 28 patients
underwent surgery for the FOAI. Of these, 15
Table 2. Univariate analysis of clinical characteristics of
patients with fungal osteoarticular infections (FOAIs) with
sinus involvement compared with those of patients with










Median age in years (range) 51 (29–63) 53 (26–89) 0.8
Male 5 ⁄ 10 (50%) 10 ⁄ 18 (56%) 0.9
Haematological malignancy 10 ⁄ 10 (100%) 16 ⁄ 18 (89%) 0.5
Haematopoietic
stem-cell transplant
7 ⁄ 10 (70%) 9 ⁄ 18 (50%) 0.4
Severe neutropenia 6 ⁄ 10 (60%) 6 ⁄ 18 (33%) 0.2
Signiﬁcant corticosteroid use 4 ⁄ 10 (40%) 6 ⁄ 18 (33%) 0.9
Diabetes mellitus 6 ⁄ 10 (60%) 8 ⁄ 18 (44%) 0.7
Renal insufﬁciency 4 ⁄ 10 (40%) 8 ⁄ 18 (44%) 0.7
Hepatic insufﬁciency 6 ⁄ 10 (60%) 9 ⁄ 18 (50%) 0.7
Malnutrition (serum
albumin £ 3 mg ⁄dL)
6 ⁄ 10 (60%) 12 ⁄ 18 (67%) 0.6
Indwelling catheter 7 ⁄ 10 (70%) 10 ⁄ 18 (56%) 0.6
Haematogenous spread 0 ⁄ 10 (0%) 10 ⁄ 18 (56%) 25.9 (1.3–510) 0.004
GCSF use 5 ⁄ 10 (50%) 7 ⁄ 18 (39%) 0.9
Surgery 9 ⁄ 10 (90%) 10 ⁄ 18 (56%) 0.09
Overall mortality at 12 weeks 4 ⁄ 10 (40%) 7 ⁄ 16 (43%) 0.9
aFOAIs with sinus involvement were caused by Zygomycetes (four), Fusarium spp.
(two), Aspergillus spp. (two), Candida tropicalis (one), and Exserohilum sp. (one).
There were two mixed FOAIs with sinus involvement, one with Rhizopus and
C. tropicalis, and one with A. ﬂavus and Fusarium.
GCSF, granulocyte colony-stimulating factor.
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patients had surgery within 1 week of diagnosis
of the FOAI. Seven patients underwent irrigation
and debridement, including one patient who also
had hardware removed. Three patients under-
went more extensive and radical surgery that
included thoracolumbar ﬁxation and arthrodesis,
and one patient had an infected toe amputated.
Most patients with sinusitis and contiguous bone
involvement underwent extensive sinus debride-
ment and excision of the sinuses, with turbinec-
tomy, septectomy, or both. One of the two
patients who had FOAI associated with the
presence of hardware had the hardware removed
following diagnosis of FOAI.
Adjunctive antifungal treatment with granulo-
cyte colony-stimulating factor was administered
to 12 patients with FOAIs; one patient with FOAI
caused by Fusarium received adjunctive antifun-
gal treatment with hyperbaric oxygen; three
patients with FOAIs caused by Fusarium, Rhizopus
and A. ﬂavus, respectively, received white blood
cell transfusions.
Outcome
The mean duration of follow-up after the diag-
nosis of FOAI was 9 months (range 11 days to
36 months). Information concerning outcome was
available for 26 patients. The overall mortality
rate at 12 weeks was 42% (11 ⁄ 26); the crude
mortality rate was 44% (9 ⁄ 20) in patients who
underwent surgery and received antifungal ther-
apy, compared with 33% (2 ⁄ 6) in patients who
received antifungal therapy alone (p not signiﬁ-
cant).
DISCUSSION
To the best of our knowledge, this is the largest
study of FOAIs among cancer patients. Moulds
were the most common cause of FOAIs among
patients with cancer, especially those with haem-
atological malignancies. Half of the patients had a
relatively acute presentation, albeit with clinical
symptoms and signs that were non-speciﬁc. Thus,
focal pain, the most common symptom, was
present in all patients, but fever, drainage and
joint instability were variably present. Most
patients had bone involvement by contiguous
extension, with the sinuses being the most com-
mon sites of bone involvement by contiguous
extension of infection. Despite the signiﬁcant
proportion of FOAIs associated with sinus
involvement, which have a distinct pathophysi-
ology compared with other types of FOAIs, there
were no differences in the clinical characteristics
and outcomes of patients with FOAIs with or
without sinus involvement. These ﬁndings are in
contrast to the view that FOAIs usually occur as a
result of haematogenous spread [3,6].
Although FOAI is rare, even in severely immu-
nocompromised individuals, it is a relatively
frequent infection in patients with chronic gra-
nulomatous disease [18]. It is of interest that
A. nidulans, an uncommon fungal pathogen with
low pathogenic potential, is the predominant
Aspergillus sp. isolated from these patients, and
has been associated with involvement of small
bones and a less favourable outcome compared
with FOAIs caused by A. fumigatus [18]. In the
present study, moulds were the fungal pathogens
isolated most frequently from patients with either
haematogenous spread or contiguous involve-
ment of bone. In addition, non-fumigatus Asperg-
illus spp., mainly A. ﬂavus and A. terreus,
comprised the majority of Aspergillus isolates.
Aspergillus and Zygomycetes were the most com-
mon fungal pathogens found in patients who had
sinusitis with contiguous bone involvement. The
presence of mixed FOAIs caused by Candida spp.
and moulds might reﬂect the fact that the study
population comprised heavily immunocompro-
mised patients. Although it is difﬁcult to account
for the pathogenicity of Candida spp. in mixed
FOAIs with sinus involvement, it is tempting to
speculate that tissue damage caused by Candida
could facilitate the subsequent development of
angioinvasive mould infection.
The published literature concerning FOAIs
includes a heterogeneous spectrum of diseases
with different prognoses [4–6,8,9,12,13,15–17,19–
24], and there is no standard treatment for
patients with FOAIs. More speciﬁcally, there is
no consensus on the optimum dose and duration
of antifungal therapy, the value of combination
antifungal therapy, or the timing and extent of
adjunctive surgery [3,24]. Most authorities believe
that incomplete debridement of a bone infection
will result in treatment failure, and that radical
debridement of infected or necrotic bone is
particularly important in a compromised host
[19,23]. Historically, the most common therapy
for FOAIs has consisted of amphotericin B com-
bined with surgical debridement [4,9,11,13,15,21].
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Stratov et al. [12] showed that cure rates were
14% when amphotericin B was used alone,
compared with 75% when it was combined with
surgery. Similar outcomes have been noted in
case reports of FOAIs caused by other moulds,
including Fusarium, S. apiospermum and Zyg-
omycetes [10,11,14,15].
Most of the patients in the present study
underwent aggressive surgery within 1 week of
diagnosis of an FOAI. However, early and aggres-
sive surgical intervention had no apparent inﬂu-
ence on outcome. Other factors might have
contributed to the overall outcome, such as the
relatively late diagnosis in many patients, and the
fact that almost half of the patients had an
advanced or treatment-refractory malignancy.
The recent availability of potent oral azoles
might revolutionise the treatment of FOAIs. A
recent study of voriconazole for the treatment of
bone aspergillosis [22] showed a response rate
of 83% in patients without underlying
immunosuppression, compared with 43% among
immunocompromised patients. In addition,
there was no apparent difference in outcome
between patients who underwent surgery and
received antifungal therapy, and those who
received antifungal therapy alone. The ability
to switch the route of voriconazole administra-
tion from intravenous to oral is an additional
beneﬁt of this drug in the management of
FOAIs caused by moulds such as Aspergillus
spp. Overall, voriconazole, an agent with fungi-
cidal activity against Aspergillus, might become
the treatment of choice, and might also obviate
the need for surgical debridement in selected
cases of FOAIs when combined with timely
diagnosis.
Limitations of the present study include its
retrospective nature, the relatively small study
population, and the lack of controlled groups
with antifungal monotherapy, combined antifun-
gal therapy, or antifungal therapy with surgery.
Another limitation of the study, as in other
studies on osteoarticular infections, is the deﬁni-
tion of outcome. Most studies have offered
various deﬁnitions, e.g., cure, improvement, erad-
ication, failure and recurrence, with each deﬁni-
tion having a different meaning that makes
comparisons among studies difﬁcult. In addition,
it is difﬁcult to separate the effects of the infec-
tion and its treatment from the effects of
co-morbidities that can affect mortality.
In conclusion, FOAIs are rare, yet severe,
manifestations of localised or systemic mycoses
in cancer patients, seen typically in patients with
haematological malignancies, with moulds being
the predominant causes.
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